Ranbaxy Laboratories' desire to quickly launch products in the US market and bag six month exclusive marketing opportunities,http://www.makelocks.com/ provides high quality industrial locks and locking systems.http://www.floorpolishingpad.com/,Products: Finglee devote to supplying more professional surface soution product,diamond cutting tools,abrasive tools,etc.High quality,reasonable price. which promised windfall gains, led to most of the data fudging and other malpractices in the company, two former executives of the company told ET.
"Most of the tampering happened at the time of filing the Abbreviated New Drug Applications (ANDAs) to US Food and Drug Administration in the hope of getting a first to file (FTF) in the US market," said a senior executive of the company who did not want to be identified.http://www.existmachinery.com/,was founded in 2005 and covers an area of 20,000 sq.m. with a building area of 15,000 sq.m.,titanium supplier supply Titanium wires,Titanium Sheets and plates,Titanium flanges,Titanium fittings,Ti-Ni shape memory alloys,cast Titanium alloys. US has a provision under Hatch Waxman law where generic drug makers can make a killing during a six month window of marketing exclusivity if they file the first valid ANDAs with US FDA.http://www.sihongfilter.com/,We have accumulated experience in filtration and could provides innovative solution to your filtration work. This is an incentive given by the US FDA to encourage launch of cheaper generics.
By 2008, Ranbaxy had built up one of the most robust and enviable pipeline of first to file opportunities in the generic industry. The company had a pipeline of 18-20 FTFs, targeting a combined innovator market of $27 billion, Milind Bhangale of IL&FS had said in an research note in June 2008,chinese mushroom mainly specializing farming, further processing, home-selling, and exporting for both edible mushrooms and organic vegetables. Meanwhile, we develop the ecological seeing agriculture. a week before Ranbaxy was acquired by the third largest Japanese drug giant Daiichi Sankyo. "We believe that this is one of the strongest para-IV pipelines in the global generic industry," Bhangale had noted on June 4, 2008.
